Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients

Valeriy Poroyko; Tamara Mirzapoiazova; Arin Nam; Isa Mambetsariev; Bolot Mambetsariev; Xiwei Wu; Aliya Husain; Everett E. Vokes; Deric L. Wheeler; Ravi Salgia

doi:10.18632/oncotarget.24857

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients

Valeriy Poroyko, Tamara Mirzapoiazova, Arin Nam, Isa Mambetsariev, Bolot Mambetsariev, Xiwei Wu, Aliya Husain, Everett E. Vokes, Deric L. Wheeler and Ravi Salgia _

PDF | HTML | How to cite

Oncotarget. 2018; 9:19793-19806. https://doi.org/10.18632/oncotarget.24857

Metrics: PDF 2112 views | HTML 4599 views | ?

Abstract

Valeriy Poroyko1, Tamara Mirzapoiazova1, Arin Nam1, Isa Mambetsariev1, Bolot Mambetsariev1, Xiwei Wu2, Aliya Husain3, Everett E. Vokes3, Deric L. Wheeler4 and Ravi Salgia1

1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

2Department of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA, USA

3Department of Medicine, University of Chicago, Chicago, IL, USA

4Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA

Correspondence to:

Ravi Salgia, email: [email protected]

Keywords: exosome; miRNA; NSCLC; SCLC; liquid biopsy

Received: January 12, 2018 Accepted: March 02, 2018 Published: April 13, 2018

ABSTRACT

Lung cancer is a devastating disease with overall bleak prognosis. Current methods to diagnose lung cancer are rather invasive and are inadequate to detect the disease at an early stage when treatment is likely to be most effective. In this study, a shotgun sequencing approach was used to study the microRNA (miRNA) cargo of serum-derived exosomes of small cell lung cancer (SCLC) (n=9) and non-small cell lung cancer (NSCLC) (n=11) patients, and healthy controls (n=10). The study has identified 17 miRNA species that are differentially expressed in cancer patients and control subjects. Furthermore, within the patient groups, a set of miRNAs were differentially expressed in exosomal samples obtained before and after chemotherapy treatment. This manuscript demonstrates the potential of exosomal miRNAs for developing noninvasive tests for disease differentiation and treatment monitoring in lung cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24857

Publication Alerts

Research Papers:

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients

Abstract